• head_banner_01

Tirzepatide

Lus piav qhia luv luv:

Tirzepatide yog ib qho tshiab dual agonist ntawm GIP thiab GLP-1 receptors, tsim rau kev kho mob ntawm hom 2 mob ntshav qab zib thiab rog rog. Raws li thawj-hauv-chav kawm "twincretin," Tirzepatide txhim kho insulin secretion, inhibits glucagon tso tawm, thiab txo qis qab los noj mov thiab lub cev hnyav. Peb cov high-purity Tirzepatide API yog chemically synthesized, dawb ntawm host-cell-derived impurities, thiab ua tau raws li thoob ntiaj teb cov qauv kev cai rau zoo, stability, thiab scalability.


Product Detail

Khoom cim npe

Tirzepatide API
Tirzepatide yog ib qho kev sib xyaw ua ke peptide uas ua haujlwm ua tus agonist dual ntawm ob qho tib si qabzib-nyob ntawm insulinotropic polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1) receptors. Nws sawv cev rau cov chav kawm tshiab ntawm kev kho mob incretin-raws li hu ua "twincretins", muab kev tswj hwm cov metabolism hauv cov neeg mob ntshav qab zib hom 2 thiab rog rog.

Peb Tirzepatide API yog tsim los ntawm cov txheej txheem tshuaj synthesis siab heev, kom ntseeg tau siab purity, qis impurity theem, thiab zoo heev batch-rau-batch sib xws. Tsis zoo li rDNA-derived peptides, peb cov khoom siv API yog pub dawb los ntawm cov cell cell proteins thiab DNA, txhim kho biosafety thiab kev ua raws cai. Cov txheej txheem tsim khoom tau raug kho kom zoo rau kev ntsuas kom tau raws li kev xav tau thoob ntiaj teb.

Mechanism ntawm Action
Tirzepatide ua haujlwm los ntawm ib txhij txhawb nqa GIP thiab GLP-1 receptors, muab cov teebmeem ntxiv thiab kev sib koom ua ke:

GIP receptor activation: txhim kho insulin secretion thiab tuaj yeem txhim kho kev nkag siab ntawm insulin.

GLP-1 receptor activation: inhibits glucagon tso tawm, qeeb plab hnyuv plab, thiab txo qis qab los noj mov.

Kev sib koom ua ke ua rau:

Txhim kho glycemic tswj

Txo lub cev hnyav

Txhim kho satiety thiab txo cov khoom noj kom tsawg

Kev Tshawb Fawb Kev Tshawb Fawb & Cov txiaj ntsig
Tirzepatide tau ua kom pom qhov ua tau zoo uas tsis tau pom dua hauv ntau qhov kev sim tshuaj loj (SURPASS & SURMOUNT series):

Superior HbA1c txo qis piv rau GLP-1 RAs (piv txwv li, Semaglutide)

Qhov hnyav poob mus txog 22.5% hauv cov neeg mob rog - piv rau kev phais bariatric hauv qee kis

Kev pib sai ntawm cov nyhuv thiab ruaj khov glycemic tswj kev siv mus ntev

Txhim kho cov cim cardiometabolic: suav nrog ntshav siab, lipids, thiab mob

Tirzepatide tsis yog tsuas yog hloov kho cov qauv kev kho mob rau hom 2 mob ntshav qab zib xwb tab sis kuj tshwm sim los ua qhov kev kho mob loj rau kev kho mob yuag poob thiab metabolic syndrome.

Quality & Ua raws cai
Peb Tirzepatide API:

Ua tau raws li cov qauv zoo thoob ntiaj teb (FDA, ICH, EU)

Kuaj ntawm HPLC rau qib qis ntawm paub thiab tsis paub impurities

Tsim nyob rau hauv GMP tej yam kev mob nrog tag nrho cov txheej txheem ntaub ntawv

Txhawb kev tsim khoom loj R & D


  • Yav dhau los:
  • Tom ntej:

  • Sau koj cov lus ntawm no thiab xa tuaj rau peb